J&J takes full control of retinal disease gene therapy from MeiraGTx

21 Dec 2023
firstwordpharma.com
License out/inGene TherapyPhase 3
Johnson & Johnson’s Janssen Pharmaceuticals unit agreed to buy full rights to MeiraGTxMeiraGTx’s investigational X-linked retinitis pigmentosa (XLRP) gene therapy botaretigene sparoparvovec (bota-vec), paying $130 million in upfront and near-term milestones. The therapy is currently being studied in the Phase III Lumeos trial.
In 2019, Janssen paid $100 million upfront as part of a deal with MeiraGTx to develop gene therapies for inherited retinal diseases, with the agreement including bota-vec, previously known as AAV-RGPR. MeiraGTx CEO Alexandria Forbes said the latest transaction provides “us with significant near-term cash,” extending its cash runway to mid-2026.
MeiraGTx noted that it stands to receive an extra $285 million in payments linked to the first commercial sales of bota-vec in the US and EU. MeiraGTxMeiraGTx also entered into a commercial supply agreement and a technology transfer agreement with Janssen for bota-vec manufacturing.
Forbes suggested that the agreement allows the company to increase focus on its two late-stage clinical programmes: AAV-AQP1 in xerostomia and AAV-GAD in Parkinson’s disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.